Therapeutic Asset Ratings

461 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
pf-07248144 Non-Small Cell Lung Carcinoma	Pfizer	P2	CCC (53)
pf-08634404 Lung Disorder	Pfizer	P2	CCC (53)
pf-08634404 Non-Small Cell Squamous Lung Carcinoma	Pfizer	P2	CCC (53)
pf-08653944 Metabolic Disease	Pfizer	P2	CCC (53)
pf-08653944 Nutritional Deficiency Disease	Pfizer	P2	CCC (53)
pf-08653944 Overnutrition	Pfizer	P2	CCC (53)
pf-08653945 Metabolic Disease	Pfizer	P2	CCC (53)
pf-08653945 Nutritional Deficiency Disease	Pfizer	P2	CCC (53)
pf-08653945 Overnutrition	Pfizer	P2	CCC (53)
Ponsegromab Colorectal Cancer	Pfizer	P2	CCC (53)
Ponsegromab Non-Small Cell Lung Carcinoma	Pfizer	P2	CCC (53)
Ponsegromab Pancreatic Neoplasm	Pfizer	P2	CCC (53)
PREDNISONE TABLETS Non-Small Cell Squamous Lung Carcinoma	Pfizer	P2	CCC (53)
PREDNISONE TABLETS Lung Disease	Pfizer	P2	CCC (53)
Rybelsus Diabetes Mellitus	Pfizer	P2	CCC (53)
Talzenna BRCA1-Related Cancer Predisposition	Pfizer	P2	CCC (53)
Vepdegestrant Castration-Resistant Prostate Carcinoma	Pfizer	P2	CCC (53)
Vepdegestrant Non-Small Cell Lung Carcinoma	Pfizer	P2	CCC (53)
(+)-VINCRISTINE Lung Disease	Pfizer	P2	CCC (53)
Osivelotor Sickle Cell Disease	Pfizer	P2/3	CCC (53)
Calaspargase Pegol Lung Cancer	Pfizer	P3	CCC (52)
Cmp 001 Non-Small Cell Lung Carcinoma	Pfizer	P3	CCC (52)
Cmp 001 Neoplasm	Pfizer	P3	CCC (52)
Ivuxolimab Non-Small Cell Lung Carcinoma	Pfizer	P3	CCC (52)
Ivuxolimab Neoplasm	Pfizer	P3	CCC (52)

Showing 201 to 225 of 461 assets